AVR

Anteris Technologies Global Corp.

$5.89

-0.84%
SectorHealthcareIndustryMedical DevicesCountryAustralia

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Source: Yahoo Finance
AI summary

Price & performance

1M-13.0%
3M-34.3%
YTD+19.7%
1Y+48.9%
52-week range—
Beta1.69
Full chart and returns against a benchmark

Q-Score

48/ 100

Quality against peers; 50 is the peer median.

Growth38
Risk53
Performance60
Valuation49
Profitability44
Leverage54
Sentiment50
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.9M-29.2%
Net income-$94.1M
Net margin—
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsFeb 26, 2026
Filings, findings and the timeline

Revenue exposure

16%of revenue from outside the US
United States84%
Germany14%
Australia2%
Regions, segments, customers and suppliers

Valuation

AVRIndustryP/E—29.61P/S—3.49EV/EBITDA—18.38P/B2.533.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report
EPS estimate$-0.31
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate